Political stalemate in Washington is raising the possibility of a partial government shutdown that could limit FDA’s ability to review NDAs. While the agency would be able to continue ongoing drug reviews during a shutdown, FDA could be barred from accepting new applications.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,